AKT1 and breast cancer: The increased cytotoxicity of Akt inhibition in doxorubicin-resistant MCF7 breast cancer cells points to a potential use of such a drug class in ER positive breast cancer, in particular if resistance to anthracycline has developed and Akt phosphorylation levels are elevated.